Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-δ Inhibitor Therapy
Blood (2017)
  • Anthony R. Mato, University of Pennsylvania
  • Bruce D. Cheson, Georgetown University
  • Nicole Lamanna, Columbia University Medical Center
  • John M. Pagel, Cancer Institute
  • Frederick Lansigan, Dartmouth–Hitchcock Medical Center
  • Paul M. Barr, University of Rochester
  • Jeffrey J. Pu, Pennsylvania State University
  • Colleen Dorsey, University of Pennsylvania
  • Elizabeth T Chatburn, University of Pennsylvania
  • Jakub Svoboda, University of Pennsylvania
  • Stephen J. Schuster, University of Pennsylvania
  • Eline Luning-Prak, University of Pennsylvania
  • Patricia Tsao, University of Pennsylvania
  • Andrea Sitlinger, Duke University
  • Chaitra S. Ujjani, Georgetown University
  • Dana Paskalis
  • Peter Sportelli, Brigham and Women's Hospital
  • Hari P Miskin
  • Michael S. Weiss
  • Danielle M. Brander, Duke University
Link
Disciplines
Publication Date
December 7, 2017
Citation Information
Anthony R. Mato, Bruce D. Cheson, Nicole Lamanna, John M. Pagel, et al.. "KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-δ Inhibitor Therapy" Blood Vol. 130 (2017) p. 4314 - 4314
Available at: http://works.bepress.com/john-pagel/5/